(Q36832926)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Prognostic factors in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1

Roberto Bergamaschi

1 reference

16 August 2017

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

International Review of Neurobiology

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

423-447

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Oligoclonal band number as a marker for prognosis in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The optic neuritis treatment trial: three-year follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Disability and Mortality in a Cohort of Multiple Sclerosis Patients: A Reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Multisequence MRI in clinically isolated syndromes and the early development of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Multiple Sclerosis: Disability and Mortality in a Cohort of Clinically Diagnosed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Clinical characteristics and long term prognosis in early onset multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Factors associated with a rapid course of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Can CSF predict the course of optic neuritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Visual and motor evoked potentials in the course of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Childhood-juvenile multiple sclerosis: clinical characteristics and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Predictors of relapse rate in MS clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Evoked potentials in suspected multiple sclerosis: diagnostic value and prediction of clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Age-dependent T cell tolerance and autoimmunity to myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Predicting multiple sclerosis at optic neuritis onset

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Neuropathology of multiple sclerosis-new concepts.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Prognostic factors for survival in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Predicting the Outcome of Optic Neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Multiple sclerosis after age 50

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The natural history of recurrent optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Age at onset, initial symptomatology and the course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Early prognostic factors for disability in multiple sclerosis, a European multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Magnetization transfer can predict clinical evolution in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Course and prognosis in early-onset MS: comparison with adult-onset forms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Methods in health service research. An introduction to bayesian methods in health technology assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Is optic neuritis more benign than other first attacks in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Disability progression in multiple sclerosis is slower than previously reported.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Bayesian analysis: what does it add to studies of the natural history of MS?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2807%2979019-0

7 January 2021

10.1016/S0074-7742(07)79019-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17531853%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference